SOURCE: digiMedical Solutions, Inc.

March 27, 2008 09:00 ET

digiMedical Solutions, Inc.™ Signs Contract With John P. Landi, M.D., Medical Director of Vanish Vein and Laser Center in Naples, Florida, in Support of $10 Million 2008 Revenue Goal

Contract Follows Recent Sales Expansion in Florida Markets

COLLEYVILLE, TX--(Marketwire - March 27, 2008) - digiMedical Solutions, Inc. (PINKSHEETS: DGMS) announced today that the Company has signed a contract with John P. Landi, M.D., Medical Director of Vanish Vein and Laser Center in Naples, Florida, to implement the digiRX system and digiReauth call center services. The system and services will provide digital prescription handling for Dr. Landi's office and will take over the prescription reauthorization processing and refill management services. This contract follows digiMedical's recent announcement of increasing the sales team in the Naples and Fort Myers, Florida, markets to expand the Company's regional footprint and support the Company's $10 million 2008 revenue goal.

Dr. Landi stated, "The digiRX digital prescription handling system will help protect us against prescription fraud. Recently we have seen several instances in which patients altered the quantity in their prescriptions. digiRX will protect us from forged prescriptions and clear up much of the malpractice risk associated with patients doing this. Also, the digiReauth system will help reduce the amount of phone calls to our office, so nurses will have more face-time for patients."

digiMedical Solutions, a Microsoft Partner, with operations in Texas and Florida, has built its own suite of proprietary software to handle prescriptions digitally from the physician's office to the pharmacy, securely and in compliance with all DEA and HIPAA requirements. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and now digiAccounting and the Company owns and operates five pharmacies throughout Texas and Florida.

Company Information and Updates

To be added to digiMedical's corporate e-mail list for shareholders and interested investors or to receive more information on the company, please send an e-mail to ir@digimedical.com.

About Vanish Vein and Laser Center (http://www.vanishvein.com/about.cfm)

Vanish Vein and Laser Center, located in Naples, FL, is a state of the art Vein Center established in 2002, dedicated to the complete eradication of unwanted veins anywhere in the body, from varicose and spider veins in the legs to unsightly veins on the hands, body and face. Modalities of treatment include laser vein ablation, venous closure, percutaneous ultrasonic directed sclerotherapy, foam sclerotherapy as well as microphlebectomies and venous stasis ulcer treatment.

About digiMedical Solutions, Inc.™

digiMedical Solutions, Inc.™ (www.digimedical.com) is a pharmacy and medical technology company focused on developing next generation digital medical technology with an emphasis on digital prescriptions (d-prescriptions) that will more closely align the doctor, pharmacist and patient. The company's planned growth will come from three channels: direct marketing of the company's wireless base d-prescription technology to doctors, acquisition of independent pharmacy chains and the sale of certain territories to "market partners" licensed to exploit the digiMedical Solutions™ model. digiMedical Solutions, Inc.™ currently owns and operates five (5) pharmacies located in Texas and Florida. digiMedical Solutions™' unique business model brings doctor, patients and pharmacies into next generation medical technologies.

Forward-Looking Statement

Statements included in this press release which are not historical in nature, are intended to be, and are hereby identified as "Forward-Looking Statements" for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements may be identified by words including "anticipate," "await," "envision," "foresee," "aim at," "believe," "intends," "estimates" including without limitation, those relating to the company's future business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company's filings with the U.S. Securities and Exchange Commission for additional information and a presentation of the risks and uncertainties that may affect the company's business and results of operations.

Contact Information